MedTrace Logo

To Assess the Safety, Tolerability, Pharmacokinetics and Pharmakodynamics of AZD2820 After Multiple Ascending Doses

NCT01469923 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2012-07-24

No results posted yet for this study

Summary

This is a randomised and single-blind, placebo-controlled study to investigate the safety, tolerabilty, pharmacokinetics and pharmacodynamics of repeated and ascending doses of AZD2820 to obese but otherwise healthy male subjects.

Conditions

Interventions

DRUG

AZD2820

Ascending subcutaneous injections of AZD2820 once daily for 14 days in the abdomen

DRUG

Placebo

Ascending subcutaneous injections of placebo for AZD2820 once daily for 14 days in the abdomen

Sponsors & Collaborators

Principal Investigators

  • James Ritter, BM BCH, MRCP, FRCP · QLON

  • Mark Berner Hansen, PHD · AstraZeneca Mölndal, Sweden

  • Mirjana Kujacic, PHD · AstraZeneca Mölndal, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01469923 on ClinicalTrials.gov